14 news items
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
PYXS
SNDX
10 Jun 24
NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
PYXS
30 May 24
focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $7 Price Target
PYXS
16 May 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
PYXS
14 May 24
generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
PYXS
9 May 24
focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief
38jyq59voe21ebsxqxlinsk52ajy61mkgfvweqhe
PYXS
7 May 24
Jefferies analyst Farzin Haque assumes Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Target of $10.
2xj7 dbelzrvp5r2rksp2bcfs3snh5tbm8nxrys
PYXS
10 Apr 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $7 price target.
lrsvclltp32ikmf
ABAT
ABIO
ACORQ
3 Apr 24
to Buy and announced a $6 price target.
Dave & Buster's Entertainment, Inc
7xiswcrnldxzxwttdih8m3dobi4dan3mwgza6
ALTM
ATAI
CALM
3 Apr 24
Ramakanth reiterated Ocugen with a Buy and maintained a $7 price target.
Pyxis Oncology, Inc
v4d9az8x4furb tr0
PYXS
28 Mar 24
focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee
tvtx9mrmik5i7ny8ell2pto84jxuu6ydiopvzha01 5lsw4y1ox
PYXS
27 Mar 24
focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights
oqnfq4u9qm17q640bce7m zaddabzd4r79x6w4ppyrp4ttjwl8xxopo
PYXS
22 Mar 24
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $7 price target.
7a9jdxchsa5pa7txmjxw53dx25hmacy8ti244da9wwbkdxu6bfkbzz
PYXS
22 Mar 24
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $4 to $7.
dk6vrbji6x8a9xrv4h4r83n1qq18ri9md0yewh5jej3lmjafoiqf52qalh9s
PYXS
21 Mar 24
to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update
- Prev
- 1
- Next